Kiniksa Pharmaceuticals International, plc officer John F. Paolini filed a Form 144 notice on October 30, 2026, proposing the sale of 96,000 Class A Ordinary Shares acquired through a cashless employee stock option exercise on the same date.

Key Highlights

  • Seller and role: John F. Paolini, listed as an Officer of Kiniksa Pharmaceuticals International, plc, is the person for whose account the securities are to be sold.
  • Shares proposed for sale: 96,000 Class A Ordinary Shares, with an aggregate market value of $8,930,275.00 according to the filing.
  • Acquisition method: The shares were acquired on October 30, 2026, via an employee stock option exercise, with payment described as "Broker Payment for Cashless Exercise."
  • Shares outstanding: The filing states 48,836,965 Class A Ordinary Shares were outstanding at the time of the notice.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 plan adoption date of July 29, 2026, and notes that "the options on this filing may be sold over various dates."
  • Exchange and broker: The securities are listed on NASDAQ, and the named broker is Charles Schwab & Co., Inc., located in Westlake, TX.
  • Prior sales: The filing reports nothing to report for securities sold during the past 3 months.

Paolini Proposes Cashless Option Exercise Sale of 96,000 Kiniksa Shares

According to the Form 144 filing, John F. Paolini, an officer of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), submitted a notice of proposed sale of securities on October 30, 2026. The filing discloses that 96,000 Class A Ordinary Shares are to be sold, with the aggregate market value reported as $8,930,275.00. The shares represent a portion of the company's reported 48,836,965 outstanding Class A Ordinary Shares.

The filing states that the securities were acquired on October 30, 2026, through an "Employee Stock Option Exercise," with the nature of payment identified as "Broker Payment for Cashless Exercise." The shares were acquired from Kiniksa Pharmaceuticals, Ltd. The filing further notes that a Rule 10b5-1 trading plan was adopted on July 29, 2026, and that "the options on this filing may be sold over various dates," indicating the proposed sales may occur across multiple dates rather than in a single transaction.

The designated broker for the proposed sale is Charles Schwab & Co., Inc., based in Westlake, Texas. The filing reports no securities of the issuer sold by Paolini during the prior three months. The approximate date of sale listed in the filing is October 30, 2026, and the notice was signed by John F. Paolini.

What Was Disclosed

Kiniksa Pharmaceuticals International officer John F. Paolini filed a Form 144 to propose the sale of 96,000 Class A Ordinary Shares, acquired via a cashless stock option exercise, with an aggregate market value of $8,930,275.00 and a 10b5-1 plan adoption date of July 29, 2026.